Novartis | Jotup

The Considered Ramps Up Management Structure With String of Creative VP Hires Spanning Medical to Design

Retrieved on:

Tuesday, March 26, 2024

Lynx, AstraZeneca, Science, Digital, Health, Novartis, Nature, Creative director, Creativity, Gold, HCP, Reality–virtuality continuum, Medicine

It was, in fact, the agency's groundbreaking approach, model and, of course, team, that attracted her to the VP Medical Director role.

Key Points:

It was, in fact, the agency's groundbreaking approach, model and, of course, team, that attracted her to the VP Medical Director role.
"The Considered is committed to moving the needle in healthcare marketing by pushing boundaries wherever possible to engage and activate our audiences," she notes.
Nowadays, as Design Director, it's about setting the standards high by recognizing and showcasing what great design is."
The string of new VP hires at The Considered comes on the heels of several award wins for the agency.

Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

Retrieved on:

Monday, March 25, 2024

Multiple myeloma, Dow Medical College, University, Rachel Haurwitz, Hematology, BCMA, Novartis, Patient, SAN, NCI-designated Cancer Center, European Hematology Association, Merck, Cancer, Reindeer, Society, Therapy, Drug development, Transplant, Lymphoma

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

Key Points:

SAN DIEGO, March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
"Syed brings to Poseida an impressive combination of industry leadership and highly specialized drug development experience in cell therapy, and I am excited to welcome him to our leadership team during this important period of execution across our clinical stage CAR-T portfolio," said Kristin Yarema, Ph.D., President and Chief Executive Officer of Poseida.
Dr. Rizvi most recently served as Chief Medical Officer of Caribou Biosciences, where he was responsible for overall strategy and execution of all clinical development programs.
Prior to joining Caribou, he served as Chief Medical Officer at Chimeric Therapeutics, where he helped build the company's pipeline by licensing programs from leading universities and progressing existing programs through the clinical development process.

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on:

Monday, March 25, 2024

Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points:

This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium

Retrieved on:

Thursday, March 21, 2024

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland. This year's event marked the tenth year of bringing together Genedata customers to share best practices and demonstrate how they increase efficiency and productivity across entire organizations by leveraging the Genedata Biopharma Platform.

Key Points:

BASEL, Switzerland, March 21, 2024 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the successful conclusion of the 10th Annual Genedata Biopharma Partner Symposium, held over 2 days from March 6–7, 2024 in Basel, Switzerland.
The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
"The Genedata Biopharma Partner Symposium has firmly established itself as a community platform to exchange pioneering work in digitalizing biopharma R&D and establishing best practices based on the Genedata software platform.
The record participation this year underscores the leading position of the Genedata Biopharma Platform within the biopharma industry," said Othmar Pfannes, Ph.D., CEO of Genedata.

HemoSonics Named to Fast Company's 2024 World's Most Innovative Companies List

Retrieved on:

Thursday, March 21, 2024

Organization, Blood transfusion, Novartis, Patient, Hospital, AI, Hope, Bristol Myers Squibb, Operating, Cartridge, Intensive care medicine, Amgen, Blood, FDA, Medicine, Pharmaceutical industry

DURHAM, N.C. , March 21, 2024 /PRNewswire/ -- HemoSonics, a medical device company focused on acute bleeding management, today announced it has been named to the prestigious list of Fast Company's Most Innovative Companies for 2024. The annual Fast Company flagship awards spotlight companies at the forefront of their respective industries and recognize organizations and products that are transforming industries through their innovations, setting new standards, and achieving remarkable milestones that are moving the world forward. HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.

Key Points:

HemoSonics joins previous Fast Company Most Innovative Company winners, including Abbott, Bristol Myers Squib, Novartis, Amgen, Scopio Labs and others.
The World's Most Innovative Companies is Fast Company's hallmark franchise and one of the year's most anticipated awards for groundbreaking innovations.
Fast Company's editorial team identified the 2024 Most Innovative Companies driving progress worldwide and across industries, evaluating thousands of submissions through a competitive application process.
We face daunting challenges on many fronts, but the solutions we celebrate in Most Innovative Companies give me plenty of hope about the future."

Former UN Peacekeeper Shares How Business Leaders Can Harness Humility to Unlock Leadership's Winning Edge In A Complex World

Retrieved on:

Tuesday, March 19, 2024

Humility, Face, The New York Times, Novartis, König, United Nations, Harvard Business School, Barnes & Noble, Thought, Publishing, Good, Multimedia, UN, Best Buy, Management

The book presents a new way of thinking about leadership and power that centers humility, rather than heroics.

Key Points:

The book presents a new way of thinking about leadership and power that centers humility, rather than heroics.
When Koenig signed up to be a NATO peacekeeping commander and United Nations peacekeeper in his fifties, he thought he knew a thing or two about leadership.
"Practicing Radical Humility helps you build deep engagement while at the same time delivering stellar bottom-line business results."
Radical Humility has received praise from experts in the field of leadership, including:
"Radical Humility is a game-changing book that redefines leadership in the modern world."

Everest Medicines Strengthens Management Team with Appointments of Chief Medical Officer and Chief Product Officer

Retrieved on:

Monday, March 18, 2024

Novartis, NDA, Messenger, Greater China, HKEX, File, Vaccine, Amgen, Marketing, Lead, Pharmaceutical industry

SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.

Key Points:

SHANGHAI, March 17, 2024 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK, "Everest," or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative medicines and vaccines, today announced that the company has strengthened its management team with the appointments of Ms. Sandra Zeng as Chief Medical Officer and Mr. Rico Liang as Chief Product Officer.
Ms. Sandra Zeng has been appointed Chief Medical Officer in charge of the clinical development team and cross function collaboration to bring more in-house developed and in-licensed innovative products in China.
Mr. Rico Liang has been appointed Chief Product Officer overseeing the Company's medical affairs and marketing departments.
We welcome Ms. Zeng and Mr. Liang as our new Chief Medical Officer and Chief Product Officer who bring to Everest decades of relevant global and China experience to help accelerate our strategic growth goals," said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.

Rare Disease Diversity Coalition Honors Champions and Unveils Resources at 2nd Annual Rare Disease Day Reception

Retrieved on:

Thursday, March 14, 2024

Novartis, Organization, Barrier, Disease, Health equity, Therapy, Rare disease, Vertex Pharmaceuticals, FDA, Pharmaceutical industry

WASHINGTON, March 14, 2024 /PRNewswire/ -- The Rare Disease Diversity Coalition (RDDC) proudly hosted its 2nd Annual Rare Disease Day Reception and 1st Annual RISE (Resilient, Impassioned, Strong, Empowered) AWARDS on February 28, 2024, at Long View Gallery in Washington, DC.

Key Points:

WASHINGTON, March 14, 2024 /PRNewswire/ -- The Rare Disease Diversity Coalition (RDDC) proudly hosted its 2nd Annual Rare Disease Day Reception and 1st Annual RISE (Resilient, Impassioned, Strong, Empowered) AWARDS on February 28, 2024, at Long View Gallery in Washington, DC.
The event, attended by a larger audience than last year, demonstrated the growing momentum within the rare disease community.
The highlight of the evening was the awards ceremony, which honored nine outstanding contributors to the rare disease community, including individuals, organizations, and legislative champions.
Looking ahead, RDDC is energized by the support, stories, and successes shared at this year's Rare Disease Day Reception.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on:

Thursday, March 14, 2024

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB).

Key Points:

There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
"Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.

Biotech's Role in Addressing the Pancreatic Cancer Emergency

Retrieved on:

Thursday, March 14, 2024

VANCOUVER, BC, March 14, 2024 /PRNewswire/ -- USA News Group - Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working diligently to improve the chances of those who receive this dire diagnosis. Recently, in late 2023, researchers at the Mayo Clinic made a discovery that advances knowledge of how pancreatic cancer spreads and identified a new potential therapeutic target along the way. With the American Cancer Society projecting a record year for new cancer cases in 2024, and Europe facing a pancreatic cancer emergency, it's important to focus on the advances being made in the biotech sector that are giving hope to patients and their families. Among the developers making gains include Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Novartis AG (NYSE: NVS), ImmunityBio, Inc. (NASDAQ: IBRX), Aclaris Therapeutics, Inc. (NASDAQ: ACRS), and Nuvation Bio Inc. (NYSE: NUVB).

Key Points:

There is a point of optimism to build upon, as the Pancreatic Cancer Action Network (PanCAN) has stated the five-year survival rate for pancreatic cancer has increased to 13% .
"Combining pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic cancer program and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients."
It will focus on patients with pancreatic cancer, HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (mCRPC), and platinum-resistant ovarian cancer (PROC).
Nuvation is already undergoing dosing in the Phase 1 monotherapy study of NUV-868 in solid tumors in patients with pancreatic cancer, ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC), triple-negative breast cancer and other solid tumors.